Asher Bio raises USD 55 Million in Series A financing
Asher Biotherapeutics, a biotechnology company developing exactly targeted immunotherapies for cancer and other diseases, raised USD 55 Million in Series A financing.
Third Rock Ventures led the round with participation from Boxer Capital of Tavistock Group, Invus, Y Combinator and MBC Biolabs.
Asher Bio is pioneering a new way to immunotherapy, called cis-targeting, which seeks to selectively activate only the immune cell-types that drive a desired immune response, thereby addressing the inherent limitations of immunotherapies attributable to their heterogeneous effects on multiple cell types.
The most...
